Shots:

• Incyte to receive $35M up front & is eligible to receive an additional ~$82.5M as development- regulatory & commercial milestones along with royalties. The collaboration will accelerate the development of tafasitama in China
• InnoCare to obtain rights to develop & exclusively commercialize tafasitamab in hematology & oncology in mainland China- Hong Kong- Macau & Taiwan
• Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting mAb. In Jun'21- EMA’s CHMP has issued a positive opinion recommending CMA of tafasitamab + lenalidomide for r/r DLBCL who are not eligible for ASCT while EC is currently reviewed CHMP opinion to grant marketing authorization in EU

Ref: Businesswire | Image: List23